Company Focus
Novo Nordisk
Latest Novo Nordisk News
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Related News
Insights
Company Spotlight
Acadia Pharmaceuticals (Nasdaq: ACAD) is a leading pharmaceutical company with a focus on bringing life-changing therapies to patients suffering from CNS diseases.
Latest News & Features of interest to Novo Nordisk
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of twice-daily oral monotherapy Fabhalta(iptacopan). 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Shares in Teva Pharmaceutical Industries closed more than 5% higher on Wednesday. 5 December 2024
Biotechnology
Privately-held Muna Therapeutics, a Danish biotech focused on neurodegenerative diseases, has announced a research alliance with UK pharma major GSK to identify and validate novel drug targets for the treatment of Alzheimer’s disease. 5 December 2024
Biotechnology
The global precision medicine market is projected to expand significantly, with an estimated growth of $66 billion between 2024 and 2028, according to Technavio. 5 December 2024
Biotechnology
US CNS specialist Relmada Therapeutics lost 77% of its stock market value on Wednesday, dropping its share price well below $1. 5 December 2024
Pharmaceutical
US drugmaker Eli Lilly enjoyed a good day on the obesity front on Wednesday, with the news that its GLP-1 receptor agonist tirzepatide - branded as Wegovy and Mounjaro - outscored its main rival from Novo Nordisk in a Phase IIIb trial. 5 December 2024
Latest In Brief for Novo Nordisk
Biotechnology
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024
Latest Related Ones To Watch News
Venture capital firm BC Partners has entered into an agreement under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Netherlands-based Synthon, from funds advised by BC Partners. 17 December 2024
16 December 2024
7 December 2024
3 December 2024
28 November 2024
26 November 2024
21 November 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze